Abstract: An adaptive action recognizer for video that performs multiscale spatiotemporal decomposition of video to generate lower complexity video. The adaptive action recognizer has a number of processing pathways, one for each level of video complexity with each processing pathway having a different computational cost. The adaptive action recognizer applies a decision making scheme that encourages using low average computational costs while retaining high accuracy.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: System and method for classifying data objects occurring in an unstructured dataset, comprising: extracting feature vectors from the unstructured dataset, each feature vector representing an occurrence of a data object in the unstructured dataset; classifying the feature vectors into feature vector sets that each correspond to a respective object class from a plurality of object classes; for each feature vector set: performing multiple iterations of a clustering operation, each iteration including clustering feature vectors from the feature vector set into clusters of similar feature vectors and identifying outlier feature vectors, wherein for at least one iteration after a first iteration of the clustering operation, outlier feature vectors identified in a previous iteration are excluded from the clustering operation; and outputting a key cluster for the feature vector set from a final iteration of the multiple iterations, the key cluster including a greater number of similar feature vectors than any of the

Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, and intermediates of use in said processes.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: Techniques for decoupling compute and storage resources in a hyper-converged infrastructure (HCI) are provided. In one set of embodiments, a control plane of the HCI deployment can provision a host from a host platform of an infrastructure on which the HCI deployment is implemented and can provision one or more storage volumes from a storage platform of the infrastructure, where the storage platform runs on physical server resources in the infrastructure that are separate from the host platform. The control plane can then cause the one or more storage volumes to be network-attached to the host in a manner that enables a hypervisor of the host to make the one or more storage volumes available, as part of a virtual storage pool, to one or more virtual machines in the HCI deployment for data storage.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.

Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.

Abstract: Implementations provide an improved system for presenting search results based on entity associations of the search items. An example method includes generating first-level clusters of items responsive to a query, each cluster representing an entity in a knowledge base and including items mapped to the entity, merging the first-level clusters based on entity ontology relationships, applying hierarchical clustering to the merged clusters, producing final clusters, and initiating display of the items according to the final clusters. Another example method includes generating first-level clusters from items responsive to a query, each cluster representing an entity in a knowledge base and including items mapped to the entity, producing final clusters by merging the first-level clusters based on an entity ontology and an embedding space that is generated from an embedding model that uses the mapping, and initiating display of the items responsive to the query according to the final clusters.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: A method and system for displaying data content associated with a video, comprising: receiving video data for a video at the user equipment; playing the video in a user interface rendered on a display device of the user equipment; pausing the video at a selected frame; accessing, based on the selected frame, content data associated with the selected frame; and displaying information about the content data associated with the selected frame in the user interface.

Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: A perforation enhancement cap for a shaped charge contains a shell and a pack of a solid propellant disposed inside the shell. The shell has a tubular straight section and a rounded cap. The rounded cap has a hole. The propellant pack has a through hole. The straight section, the rounded cap, the hole in the rounded cap, as well as the through hole are disposed about a common longitudinal axis. The through hole has a conical frustum section with its larger base facing the inside of the enhancement cap. The enhancement cap is adapted to receive the shaped charge to-form an enhanced perforation charge assembly for perforation and fracturing the formation.

Abstract: The present application relates to a sleep evaluation display method and device and an evaluation equipment. The method includes: acquiring a sleep monitoring signal; analyzing the sleep monitoring signal in sequence based on a plurality of scoring items according to a signal parsing strategy corresponding to each of the scoring items to obtain signal parsing results corresponding to a plurality of scoring items respectively; searching for a corresponding relationship between each of the scoring items and a corresponding step scoring coefficient according to the signal parsing results corresponding to the plurality of scoring items respectively, and determining the step scoring coefficients corresponding to each of the scoring items; summarizing the step scoring coefficients of all the scoring items to obtain an overall evaluation result of the sleep monitoring signal; and prompting the overall evaluation result and the step scoring coefficients related thereto.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention relates to an initiator mixture, a composition, use thereof, a process of preparing polymer polyol, and a polymer polyol obtained by the process. The initiator mixture comprises: a first peroxide of formula (I) R1—O—O—R2, wherein R1 and R2 are independent an alkyl group or an alkanoyl group comprising 1 to 30 carbon atoms, preferably 3 to 20 carbon atoms, and more preferably 4 to 20 carbon atoms; and a second peroxide of formula (II) R3—O—O—R4—O—O—R5, wherein R3 and R5 are independently an alkyl group comprising 1 to 30 carbon atoms, preferably 3 to 20 carbon atoms, and more preferably 5 to 10 carbon atoms, and R4 is a cycloalkylene group comprising 3 to 30 carbon atoms, preferably 4 to 20 carbon atoms, and more preferably 5 to 10 carbon atoms.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.